This short communication was aimed at re-exploring the evidence contribution provided by systematic reviews and meta-analyses on pain in diabetic peripheral neuropathy (DPN) in order to provide implications for anesthetic and analgesic management. Existing evidence though limited provide sufficient information on epidemiology of DPN with prevalence rates ranging between 26-47%;annual pain medication costs of $1,004 per DPN patient;duloxetine, gabapentin, alpha lipoic acid and pregabalin were effective drugs; and consensus guidelines recommended that choice for treatment must also include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.          

                                                                                                                                                Keywords: Levels of evidence; Diabetic neuropathy; Neuropathic pain; Evidence-informed pain management; Neuroanesthesiology.